OCT onboards new shareholders after Phase I results

Oxford Cannabinoid Technologies Holdings plc (LSE: OCTP) (“OCT” or “the Company”), the pharmaceutical company developing prescription cannabinoid medicines, announces that Kingsley Capital Partners LLP (“Kingsley”), has sold 39,464,286 shares in the Company to Shareholders of Kingsley and has transferred 15,400,000 shares in the Company to employees of Kingsley.

This announcement follows a recent reorganisation of Kingsley’s relationship with its co- investors and its desire to bring on board and incentivise new members of its management team.

Clarissa Sowemimo-Coker, Chief Executive Officer of OCT, said:

“Today’s announcement is an important one. It enables a number of investors who have long been part of the OCT story to be able to express their support for the business as individual shareholders. I welcome the clarity this brings. It is a sign of growing confidence in OCT that investors want personally to become a part of our journey following last week’s Phase I announcement. I am delighted the business is able to benefit from their belief in our future mission and this clear endorsement of the progress we are making. Kingsley continues to be the largest shareholder in OCT.”

Neil Mahapatra, Non-Executive Director of OCT and Managing Partner of Kingsley Capital Partners LLP, said:

“I am excited to be buying more into OCT personally. Given the recent Phase I results, the Company appears to me to be significantly undervalued. It is for this reason that I, along with other shareholders and employees of Kingsley, have chosen to increase our direct holding in the business.”